Covidien kicks off PAD studies in Europe

Mon, 08/08/2011 - 9:46am
Mass High Tech: The Journal of New England Technology

Covidien plc (NYSE:COV) has begun enrolling patients in three studies at Belgian hospitals utilizing treatments for peripheral arterial disease (PAD), according to the Dublin-based company that has U.S. headquarters in Mansfield.

Covidien said its Definitive AR anti-restenosis study is enrolling patients at Imelda Hospital in Bonheiden, Belgium. Definitive AR is a pilot study designed to address restenosis, which is the narrowing of a blood vessel in patients with PAD, and will look at the impact of treating a diseased vessel with plaque excision prior to the use of a drug-coated balloon. The study will focus on whether removing calcified plaque will enhance the absorption of drugs delivered by a drug-coated balloon.



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.